BUZZ-Shire: Gattex, Natpara & Vyvanse possible blockbusters-UBS

** Shire (Xetra: S7E.DE - news) 3rd-top FTSE 100 riser as UBS (NYSEArca: FBGX - news) hikes TP to 6,600p vs 5,400p, saying co likely did not overpay for NPS Pharmaceuticals

** The $5.2 bln NPS acquisition gave Shire 2 key new drugs - Gattex & Natpara; UBS says both should become blockbusters

** UBS also sees scope for Vyvanse - Shire's big-selling hyperactivity drug which FDA recently approved for binge eating - to become a blockbuster

** Blog Betaville said co has sights on combining with US rare genetic diseases specialist BioMarin Pharmaceutical (NasdaqGS: BMRN - news) . Link: http://bit.ly/1ICuVHC

** Called down 0.5-1 pct in pre-market by brokers, say deal unlikely

** Shire, which was set to be bought by AbbVie (LSE: 0QCV.L - news) last year for 5,248p a share, up 1.4 pct at 5,385p (US group pulled plug on the $55 bln deal after changes to US tax rules) (RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net)